Numis Securities Ltd reaffirmed their buy rating on shares of Horizon Discovery Group PLC (LON:HZD) in a report released on Wednesday morning. The brokerage currently has a GBX 260 ($3.22) price objective on the stock.
Several other analysts have also commented on HZD. Beaufort Securities reiterated a speculative buy rating on shares of Horizon Discovery Group PLC in a research report on Wednesday, November 2nd. N+1 Singer reiterated a buy rating and issued a GBX 194 ($2.40) price target on shares of Horizon Discovery Group PLC in a research report on Wednesday, November 9th. Finally, Panmure Gordon restated a buy rating and set a GBX 205 ($2.54) target price on shares of Horizon Discovery Group PLC in a research report on Wednesday, November 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of GBX 217.25 ($2.69).
Shares of Horizon Discovery Group PLC (LON:HZD) opened at 128.75 on Wednesday. Horizon Discovery Group PLC has a 52-week low of GBX 125.00 and a 52-week high of GBX 188.06. The stock’s market cap is GBX 121.18 million. The stock’s 50 day moving average price is GBX 139.31 and its 200-day moving average price is GBX 155.62.
About Horizon Discovery Group PLC
Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company’s gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.
Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.